[Immunoreactive disorders and their correction in patients with rhegmatogenous retinal detachment complicated by vitreoretinal proliferation]. / Narusheniia immunoreaktivnosti i ikh korrektsiia u bol'nykh s regmatogennoi otsloikoi setchatki, oslozhnennoi vitreoretinal'noi proliferatsiei.

Examination of the immunologic state of 73 patients with rhegmatogenous retinal detachment complicated by vitreoretinal proliferation has revealed correlation between the severity of the latter and disturbances in the immune state of the patient's body. 44% of patients with the stage C and 62% of patients with the stage D have immunodeficiency expressed by reduced level of T- and B-lymphocytes and their subpopulation. It is shown that disturbances in immunoreactivity can serve as an unfavourable sign for prognosis of effectiveness of surgical intervention in patients with rhegmatogenous retinal detachment. In 70% of the patients these disturbances lead to unfavourable outcome of the operation. For normalization of the revealed disturbances in the immune state, immunomodulator thymaline was used in a complex treatment of 17 patients. The preparation rose the effectiveness of the treatment in 78% of patients and reduced the number of postoperative complications. It is recommended to study the immunologic state of the patient with rhegmatogenous retinal detachment complicated by vitreoretinal proliferation for the purpose of its further correction and a higher effectiveness of surgical treatment of such patients.

[Characteristics of the immune status of patients with uveal melanoma during the performance of organ-preserving treatment]. / Osobennosti immunnogo statusa bol'nykh uveal'nymi melanomami v protsesse provedeniia organosokhrannogo lecheniia.

The paper presents data about changes in the immune status of patients with uveal melanoma in the process of organ-preserving treatment. The presence of 2 types of reaction on the treatment are shown. They are characterized by intensification or depression of the cellular immunity, in particular of its T-cellular link. The type of reaction depends on the initial state of the immune reactivity of the body, the size of the tumor and the type of the injurious factor. The increase of immune reactivity correlates with the best clinical outcomes of the treatment. This allows to use the determination of the immune status in prognosticating the outcome of treatment.